Big Gain For Trevi Therapeutics, Inc.

Mon, Mar 10, 2025 at 08:11 PM
Big Gain For Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. (TRVI:NASDAQ) jumped higher at $6.07, a gain of 41.2%. On Mon, Mar 10, 2025, TRVI:NASDAQ hit a New 2-Week High of $6.07. The stock appeared on our News Catalysts scanner on Mon, Mar 10, 2025 at 02:11 PM in the 'BIOTECH' category. From Mon, Feb 24, 2025, the stock recorded 50.00% Up Days and 54.55% Green Days

About Trevi Therapeutics, Inc. (TRVI:NASDAQ)

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson's disease.

Share
Get Lifetime 50% Off Premium Subscription
$19.99 USD
Limited-Time Discount
$9.99 USD
monthly
Signup 7 Days Trial. No Credit Card Required!
Ever wanted to explore stocks that have recently spiked... stocks moving sideways... gaps... or other trends? You're in the right place! Check StockTreats features.